Developing Differentiated Medicines 

PureTech is developing medicines for devastating diseases including intractable cancers, lymphatic, GI diseases, CNS disorders, inflammatory and immunological diseases.

Exploring the Brain Immune Gut (BIG) axis

24 product candidates

14 are clinical stage

1 FDA cleared product

Relationships with major pharma companies

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

Team of industry leaders and experts

Publications
Publications
Nature Neuroscience: CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Publications
Internal Pipeline
PureTech's Lymphatic Leap
Publications
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Press releases
2019-11-21
PureTech Affiliate Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Continue

Press releases
2019-11-18
PureTech Affiliate Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Continue

Press releases
2019-11-15
PureTech’s Independent Affiliate resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

Continue